Mary Jane Lim-Fat, J Bryan Iorgulescu, Rifaquat Rahman, Varun Bhave, Alona Muzikansky, Eleanor Woodward, Sydney Whorral, Marie Allen, Mehdi Touat, Xiaomei Li, Gongwen Xu, Jay Patel, Elizabeth R Gerstner, Jayashree Kalpathy-Cramer, Gilbert Youssef, Ugonma Chukwueke, J Ricardo McFaline-Figueroa, Lakshmi Nayak, Eudocia Q Lee, David A Reardon, Rameen Beroukhim, Raymond Y Huang, Wenya Linda Bi, Keith L Ligon, Patrick Y Wen
BACKGROUND: Adverse clinical events cause significant morbidity in patients with glioblastoma (GBM). We examined whether genomic alterations were associated with adverse events (AEs) in GBM patients. METHODS: We identified adults with histologically confirmed IDH-wildtype GBM with targeted next-generation sequencing (OncoPanel) at Dana Farber Cancer Institute from 2013-2019. Seizure at presentation, lymphopenia, thromboembolic events, pseudoprogression, and early progression (within 6 months of diagnosis) were identified as AEs...
January 22, 2024: Clinical Cancer Research